|
Aureon Laboratories Announces
Appointment of New CEO
Robert Shovlin promoted from President to President and CEO
YONKERS, N.Y., August 25, 2009 - Aureon Laboratories, Inc., a
specialized laboratory dedicated to advancing personalized
cancer treatment through predictive pathology, today announced
the promotion of Robert Shovlin from the company’s President to
President and Chief Executive Officer. Vijay Aggarwal, PhD will
step down as CEO, but will remain a member of the company’s
board of directors. Dr. Aggarwal will also remain actively
involved in shaping the company’s long-term strategies as Aureon
continues its evolution.
“Since launching our prognostic tests for prostate cancer last
year, our company has enjoyed rapid growth and expansion,” said
Kevin Johnson, Chairman of Aureon Laboratories. “Rob has played
a central role in leading the company and driving our success.
We are excited about the company’s future trajectory and for
what we will accomplish under Rob’s direction.”
Commenting on the transition, Mr. Shovlin said “Vijay’s
leadership and dedication have been instrumental in building
Aureon into the company it is today. I am excited to be given
the added responsibility of CEO and will continue to work
closely with Vijay as we build upon the strong foundation we
have established and expand the applications of our proprietary
technology.”
Robert Shovlin joined Aureon Laboratories in June of 2005 as
Vice President of Sales and Marketing and was subsequently
promoted to Chief Operating Officer in 2007 then President and
COO in 2008. As President and COO, Mr. Shovlin led the company’s
research and development, sales and product management
activities. In addition, he played a leading role in the 2008
commercial launch of the company’s prognostic test Prostate Px+.
Prostate Px+ helps newly diagnosed patients make more informed
treatment decisions by providing an objective and personalized
analysis of the patient’s cancer from the molecular level.
Prostate Px+ successfully identifies patients with aggressive,
life-threatening prostate cancer with greater accuracy than any
other method currently available.
Prior to joining Aureon, Mr. Shovlin was the Executive Director
of Anatomic Pathology for Quest Diagnostics Incorporated (NYSE:
DGX). Mr. Shovlin also previously held various sales and sales
management roles at DIANON Systems, Inc. He is a former Captain
in the United States Marine Corps who holds a B.S. from Penn
State University and an M.B.A. from Rutgers University.
About Aureon Laboratories
Aureon Laboratories' mission is to enable personalized patient
care through predictive pathology. Aureon has developed a high
throughput systems pathology technology platform to predict
individual clinical outcomes through the interrogation of
tissue. The platform generates and analyzes an integrated,
digital view of clinical findings, tissue micro-anatomy and
tissue molecular pathology to determine which combination of
features predicts specified individual clinical outcomes. Allied
with major cancer centers, Aureon operates a CLIA-certified and
CAP-accredited laboratory that provides predictive pathology
services to the practicing physician. For more information about
Aureon, please visit
www.aureon.com
or call 1-888-SYS-PATH.
Contact
Aureon Laboratories
Jason Alter, Ph.D.
Phone: 914-377-4036
Jason.Alter @Aureon.com
|
